519 related articles for article (PubMed ID: 27126270)
21. Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis.
Bashir A; Miskeen AY; Bhat A; Fazili KM; Ganai BA
Eur J Cancer Prev; 2015 Sep; 24(5):373-85. PubMed ID: 25569450
[TBL] [Abstract][Full Text] [Related]
22. Invasive Fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway.
Yu J; Chen Y; Fu X; Zhou X; Peng Y; Shi L; Chen T; Wu Y
Int J Cancer; 2016 Sep; 139(6):1318-26. PubMed ID: 27130618
[TBL] [Abstract][Full Text] [Related]
23. Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum.
Brennan CA; Nakatsu G; Gallini Comeau CA; Drew DA; Glickman JN; Schoen RE; Chan AT; Garrett WS
mBio; 2021 Apr; 12(2):. PubMed ID: 33824205
[TBL] [Abstract][Full Text] [Related]
24. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection.
Chen T; Li Q; Zhang X; Long R; Wu Y; Wu J; Fu X
Hum Pathol; 2018 Sep; 79():93-101. PubMed ID: 29792893
[TBL] [Abstract][Full Text] [Related]
25. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade.
Chen Y; Peng Y; Yu J; Chen T; Wu Y; Shi L; Li Q; Wu J; Fu X
Oncotarget; 2017 May; 8(19):31802-31814. PubMed ID: 28423670
[TBL] [Abstract][Full Text] [Related]
26. Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.
Repass J; Maherali N; Owen K; ;
Elife; 2016 Feb; 5():. PubMed ID: 26882501
[TBL] [Abstract][Full Text] [Related]
27. Fusobacterium nucleatum and Bacteroides fragilis detection in colorectal tumours: Optimal target site and correlation with total bacterial load.
Rye MS; Garrett KL; Holt RA; Platell CF; McCoy MJ
PLoS One; 2022; 17(1):e0262416. PubMed ID: 34995318
[TBL] [Abstract][Full Text] [Related]
28. Fusobacterium nucleatum detected simultaneously in a pyogenic liver abscess and advanced sigmoid colon cancer.
Shigefuku R; Watanabe T; Kanno Y; Ikeda H; Nakano H; Hattori N; Matsunaga K; Matsumoto N; Kanno SI; Nosho K; Hachiya A; Iwatani Y; Matsumori T; Tsukikawa S; Makizumi R; Otsubo T; Yamamoto H; Itoh F
Anaerobe; 2017 Dec; 48():144-146. PubMed ID: 28823592
[TBL] [Abstract][Full Text] [Related]
29. Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal immunochemical test for haemoglobin is a promising marker for detection of colorectal neoplasia.
Suehiro Y; Zhang Y; Hashimoto S; Takami T; Higaki S; Shindo Y; Suzuki N; Hazama S; Oka M; Nagano H; Sakaida I; Yamasaki T
Ann Clin Biochem; 2018 Jan; 55(1):59-68. PubMed ID: 28081635
[TBL] [Abstract][Full Text] [Related]
30. A prospective interventional trial on the effect of periodontal treatment on Fusobacterium nucleatum abundance in patients with colorectal tumours.
Yoshihara T; Kioi M; Baba J; Usuda H; Kessoku T; Iwaki M; Takatsu T; Misawa N; Ashikari K; Matsuura T; Fuyuki A; Ohkubo H; Matsumoto M; Wada K; Nakajima A; Higurashi T
Sci Rep; 2021 Dec; 11(1):23719. PubMed ID: 34887459
[TBL] [Abstract][Full Text] [Related]
31. Detection of Fusobacterium nucleatum DNA in primary care patient stool samples does not predict progression of colorectal neoplasia.
Aitchison A; Pearson JF; Purcell RV; Frizelle FA; Keenan JI
PLoS One; 2022; 17(6):e0269541. PubMed ID: 35658028
[TBL] [Abstract][Full Text] [Related]
32. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway.
Ito M; Kanno S; Nosho K; Sukawa Y; Mitsuhashi K; Kurihara H; Igarashi H; Takahashi T; Tachibana M; Takahashi H; Yoshii S; Takenouchi T; Hasegawa T; Okita K; Hirata K; Maruyama R; Suzuki H; Imai K; Yamamoto H; Shinomura Y
Int J Cancer; 2015 Sep; 137(6):1258-68. PubMed ID: 25703934
[TBL] [Abstract][Full Text] [Related]
33. Fusobacterium nucleatum is associated with worse prognosis in Lauren's diffuse type gastric cancer patients.
Boehm ET; Thon C; Kupcinskas J; Steponaitiene R; Skieceviciene J; Canbay A; Malfertheiner P; Link A
Sci Rep; 2020 Oct; 10(1):16240. PubMed ID: 33004953
[TBL] [Abstract][Full Text] [Related]
34. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.
Kostic AD; Chun E; Robertson L; Glickman JN; Gallini CA; Michaud M; Clancy TE; Chung DC; Lochhead P; Hold GL; El-Omar EM; Brenner D; Fuchs CS; Meyerson M; Garrett WS
Cell Host Microbe; 2013 Aug; 14(2):207-15. PubMed ID: 23954159
[TBL] [Abstract][Full Text] [Related]
35.
Gethings-Behncke C; Coleman HG; Jordao HWT; Longley DB; Crawford N; Murray LJ; Kunzmann AT
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):539-548. PubMed ID: 31915144
[TBL] [Abstract][Full Text] [Related]
36. Isolation and molecular identification of Fusobacterium nucleatum from Nigerian patients with oro-facial infections.
Nwaokorie FO; Coker AO; Ogunsola FT; Avika-Campos MJ; Gaetti-Jardim E; Ayanbadejo PO; Umeizudike KA; Abdurrazaq OT
West Afr J Med; 2011; 30(2):125-9. PubMed ID: 21984462
[TBL] [Abstract][Full Text] [Related]
37. Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies.
Xie YH; Gao QY; Cai GX; Sun XM; Sun XM; Zou TH; Chen HM; Yu SY; Qiu YW; Gu WQ; Chen XY; Cui Y; Sun D; Liu ZJ; Cai SJ; Xu J; Chen YX; Fang JY
EBioMedicine; 2017 Nov; 25():32-40. PubMed ID: 29033369
[TBL] [Abstract][Full Text] [Related]
38. Association of Antibody Responses to Fusobacterium nucleatum and Streptococcus gallolyticus Proteins with Colorectal Adenoma and Colorectal Cancer.
Genua F; Butt J; Waterboer T; Hughes DJ
Dig Dis Sci; 2023 Aug; 68(8):3300-3311. PubMed ID: 37338617
[TBL] [Abstract][Full Text] [Related]
39. Association of
Borowsky J; Haruki K; Lau MC; Dias Costa A; Väyrynen JP; Ugai T; Arima K; da Silva A; Felt KD; Zhao M; Gurjao C; Twombly TS; Fujiyoshi K; Väyrynen SA; Hamada T; Mima K; Bullman S; Harrison TA; Phipps AI; Peters U; Ng K; Meyerhardt JA; Song M; Giovannucci EL; Wu K; Zhang X; Freeman GJ; Huttenhower C; Garrett WS; Chan AT; Leggett BA; Whitehall VLJ; Walker N; Brown I; Bettington M; Nishihara R; Fuchs CS; Lennerz JK; Giannakis M; Nowak JA; Ogino S
Clin Cancer Res; 2021 May; 27(10):2816-2826. PubMed ID: 33632927
[TBL] [Abstract][Full Text] [Related]
40. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms.
Li BS; Wang XY; Xu AG; Ma FL; Ma QY; Li Z; Liu JH; Gan AH; Yu ZJ; Zhang XH; Jiang B
Clin Colorectal Cancer; 2012 Dec; 11(4):280-90. PubMed ID: 22609129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
